The Power of PrEP
To mark National Black HIV/AIDS Awareness Day on February 7, Treatment Action Group (TAG) is co-hosting a webinar “The Power of PrEP” in coalition with PrEP4All, Atlanta Black Women, AVAC, and iStrive.
To mark National Black HIV/AIDS Awareness Day on February 7, Treatment Action Group (TAG) is co-hosting a webinar “The Power of PrEP” in coalition with PrEP4All, Atlanta Black Women, AVAC, and iStrive.
This fact sheet on breakthrough COVID-19 infections among people living with HIV was co-produced by TAG and our partners the Black AIDS Institute, Southern AIDS Coalition and the COVID-19 Prevention Network.
This year’s edition of TAGline commemorates TAG’s 30th anniversary, and these articles explore TAG’s work over the years: what we've accomplished, what we've learned, the continuing obstacles to progress, and what comes next.
We, the undersigned civil society and community-based organizations, welcome the announcement by Unitaid and its partners that they have reached an agreement with Lupin Limited and Macleods Pharmaceuticals to introduce two formulations of rifapentine at competitive prices.
Four years after the Medicines Patent Pool (MPP) and AbbVie came to agreement on a voluntary license authorizing MPP to sublicense G/P to generic manufacturers to ensure commercialization in low- and middle-income countries, generic G/P is not available anywhere.
In 2021, the Global Tuberculosis Community Advisory Board (TB CAB) celebrated its tenth anniversary of advocating for community engagement in research and improved access to TB prevention, treatment, and diagnostic technologies.
A new generic version of bedaquiline produced by Macleods Pharmaceuticals in India has cleared the Global Fund’s Expert Review Panel (ERP), an independent group of experts that reviews finished pharmaceutical products and makes recommendations on their use to the Global Fund.
On May 18, 2022, Treatment Action Group (TAG), the Black AIDS Institute (BAI), and the Southern AIDS Coalition (SAC) participated in this fun and informative Instagram Live discussion commemorating HIV Vaccine Awareness. Day.
As the global Long-Acting Technologies Community Advisory Board (LAT CAB) representing 12 countries, vast civil society networks, and people living with and affected by malaira, HIV, tuberculosis, and hepatitis C across the world – in reflection of World Malaria Day on April 25, 2022 – we are shocked and united in anger at the health disparities and slow progress in meeting malaria eradication goals set out in the WHO Global Technical Strategy for Malaria 2016-2030.
A group of six leading HIV/AIDS and viral hepatitis advocates today released the following joint statement regarding recent manufacturer action against the 340B Drug Pricing Program: